医渡科技(02158)公布，2026年2月3日耗资约821.79万港元回购146.28万股股份。 ...

Core Insights - Qilu Bank has demonstrated strong performance in its 2025 mid-year results, focusing on creating a comprehensive financial service ecosystem to support private enterprises in overcoming financing challenges [1] - The bank aims to be a key player in serving the private economy by innovating the "industry service circle" to eliminate invisible financing barriers, thus enabling private enterprises to operate with greater confidence [1] Group 1: Financial Innovations and Support - Qilu Bank has launched a "blue cold chain industry chain financial solution" to address funding bottlenecks in the cold chain logistics sector, particularly for a leading enterprise in the region [3][4] - The bank provided 50 million yuan in online trade financing to a supply chain management company, specifically for expanding procurement of high-demand seafood, reducing financing costs by 1.5 percentage points and saving 750,000 yuan annually [3] - The bank has approved a total of 140 million yuan in trade financing for five compliant and high-growth seafood processing companies, significantly increasing the utilization rate of cold storage facilities [4] Group 2: Technology and Innovation Financing - Qilu Bank has introduced the "Science and Technology Loan" product to support technology-driven enterprises, successfully providing 3 million yuan to a company with a new order exceeding 90 million yuan [5][6] - The bank has developed a credit evaluation system based on big data for technology enterprises, allowing for a comprehensive assessment of their capabilities and potential, thus transforming their technological strengths into tangible assets [6] - As of June, the balance of technology loans at Qilu Bank's Liaocheng branch reached 2.18 billion yuan, reflecting a 30% increase since the beginning of the year [6] Group 3: Accounts Receivable Financing - Qilu Bank has launched the "No Recourse Domestic Factoring (Quanxin Chain)" service to provide easier financing options for small and micro enterprises facing challenges with accounts receivable [7] - The bank facilitated over 500,000 yuan in financing for two private medical technology companies to help them manage cash flow issues related to delayed receivables [7][8] - The "Quanxin Chain" product has issued loans exceeding 760 million yuan to over 170 private enterprises, effectively addressing the financing difficulties associated with accounts receivable [8]

今海医疗科技(02225)发布公告，董事会欣然宣布李斌先生获委任为公司执行董事，自2026年2月3日起 生效。李斌先生亦获委任为董事会联席主席。 ...

2月1日，医疗人工智能协同创新论坛暨医疗人工智能联盟（筹）2026年第一次学术会议在上海练秋湖华为研发中心举办。华为云在会上发布"行业AI梦工 厂"首个专区——智慧医疗专区，明确在医疗AI领域的布局，目标以技术创新破解医疗资源均衡难题，推动医疗AI普惠。 第二项重磅举措，是华为云"行业AI梦工厂"首个专区——智慧医疗专区的正式推出。据周跃峰介绍，技术只有解决行业问题，才能创造真正价值。该专区深 度融合了瑞金医院等头部医疗机构的先进临床经验，以及华为在ICT、云、AI等领域的技术沉淀与实践成果。它将为基层医院及医生、合作伙伴、开发者提 供一套覆盖场景、模型、平台到社区的端到端支撑体系，让AI真正普惠每一家医院、每一位医生、每一名患者。 第三项举措是关于生态建设。周跃峰强调，医疗AI的普惠从来不是一家企业能单独完成的使命，生态共筑才是关键，要聚产业之力，共建共享，才能让医 疗AI创新更简单。华为呼吁更多医疗机构、科技企业和开发者加入进来，共同建设智慧医疗专区。通过共建共享领先的行业模型、高质量数据集、场景化 应用与AI工具链，降低医疗AI创新的门槛，加速医疗AI的规模化落地与普惠应用。 从夯实数字底座到打造智慧医 ...

(编辑：杨燕 林辰)关键字： 医疗 近日，国科离子医疗科技有限公司完成首轮股权融资，成功募集资金8亿元。公司最终选定具有战略合 作潜力的社保基金中关村自主创新专项基金与君联资本联合领投，并获得原股东厦门国贸的追加投资， 为公司后续长远发展注入强劲动力。 本轮融资引入战略投资方，既能助力国科离子进一步强化核心技术优势，加速拓展国际市场，又能整合 资源，稳定企业战略规划，完善公司治理体系，依托公司的AI中心实现互联全国离子放疗装置、集结 优质医疗资源，以数智技术重构诊疗流程，达成强点、连线、共网的战略目标。 （国科离子公众号） ...

Group 1 - The core viewpoint is that AI has penetrated the entire healthcare industry chain, with significant growth driven by technological advancements and policy support [1][2] - AI applications in healthcare vary in maturity, with smart healthcare, particularly in medical imaging, being one of the most developed areas [2] - The global market for AI solutions in healthcare is projected to grow from $13.7 billion in 2022 to $155.3 billion by 2030, with a CAGR of 35.5% [2] Group 2 - Recent policies from multiple government departments are promoting the application of AI in healthcare, with the National Medical Products Administration prioritizing "AI medical devices" as a key development area [2] - AI medical products are being rapidly implemented, with companies like Mindray and United Imaging set to release advanced AI models in the coming years [4] - The performance of the Shenwan Pharmaceutical Index has been mixed, with a recent decline of 3.68%, underperforming the CSI 300 Index [3]

Core Viewpoint - The article highlights the increasing investment interest from southbound funds in iFlytek Medical Technology (02506.HK), indicating a positive trend in stock accumulation over recent trading days [1]. Group 1: Investment Activity - On February 2, southbound funds increased their holdings by 194,000 shares in iFlytek Medical Technology [1]. - Over the past five trading days, there were four days of net increases, totaling 319,300 shares [1]. - In the last twenty trading days, there were twelve days of net increases, amounting to 1,632,800 shares [1]. - As of now, southbound funds hold 5,491,500 shares of iFlytek Medical Technology, representing 7.1% of the company's total issued ordinary shares [1]. Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [2]. - The company's business lines include grassroots medical services, hospital services, patient services, and regional management platform solutions [2]. - Grassroots medical services consist of intelligent medical assistants and chronic disease management [2]. - Hospital services include smart hospital solutions and diagnostic assistance [2]. - Patient services encompass smart hospital patient services, post-discharge management, imaging cloud platforms, and medical devices [2]. - Regional management platform solutions involve smart health solutions and smart medical insurance [2].

Group 1 - The core point of the news is that Yidu Tech (02158) has been actively repurchasing its shares, with a recent buyback of over 880,000 shares at approximately HKD 5.65 per share, totaling around HKD 5 million, marking a new high for single-day repurchase amounts [1] - The company has conducted share buybacks for six consecutive trading days, with a cumulative repurchase amount nearing HKD 15 million, indicating a strong commitment to its buyback plan and confidence in its intrinsic value and long-term growth prospects [1] - The ongoing buyback activity is supported by the steady progress of Yidu Tech's AI healthcare business and the enhancement of its core competitiveness, highlighted by a strategic partnership with Nanshan People's Hospital in Shenzhen to develop an "AI + health management" system [1] Group 2 - Recent business achievements include surpassing 4.5 million insured individuals in the 2026 Beijing Universal Health Insurance project, demonstrating the company's strong capabilities in the healthcare service sector [2] - The launch of the "General Medicine Diagnosis AI Assistant" in collaboration with Chongqing Medical University First Affiliated Hospital has been trialed in over 20 grassroots medical institutions in Chongqing, creating a replicable digital healthcare solution [2] - Industry experts view the company's share repurchase as a positive signal for investors, reflecting confidence in profitability growth and quality improvement, which can help maintain the company's value and enhance investor expectations for future development [2]

近日，国科离子医疗科技有限公司宣布完成首轮股权融资，成功募集资金8亿元。本次融资由社保基金 中关村自主创新专项基金（君联资本担任管理人）与君联资本领投。 ...

其中，苏州多年来一直在普通地级市位居第一。作为经济"最强地级市"，苏州市统计局2月2日公布2025 年苏州市经济运行情况显示，根据江苏省地区生产总值统一核算结果，2025年苏州市实现地区生产总值 27695.1亿元，按不变价格计算，比上年增长5.4%。 苏州近年来经济转型升级走在地级市前列，工业制造业十分发达。数据显示，2025年，苏州工业"压舱 石"作用凸显。全市工业对经济增长的贡献率达53.0%。规模以上工业总产值达4.9万亿元。前六大主导 行业实现产值32088.4亿元，比上年增长4.0%，对规模以上工业总产值增长贡献率达67.3%。 1月21日，江苏爱舍伦医疗科技集团股份有限公司在北京证券交易所上市，成为2026年江苏省及苏州市 首家新增A股上市公司。另外，数据统计显示，2025年A股共计116家企业首发上市，苏州企业数量多达 12家，相当于每10家新上市公司中就有1家来自苏州，超过一线城市，位居各城市第一位。 2026.02.02 本文字数：1812，阅读时长大约3分钟 作者 |第一财经 林靖 在直辖市、省会城市、计划单列市外，一些普通地级市的经济发展也十分强劲，在区域经济发展具有重 要的带动引领作 ...